- Home
- BDRX vs GTBP Comparison
BDRX vs GTBP Comparison
Compare BDRX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | GTBP |
|---|---|---|
| Founded | 2000 | 1965 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BDRX | GTBP |
|---|---|---|
| Price | $6.81 | $0.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 09-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.58 | $0.54 |
| 52 Week High | $92.00 | $4.10 |
Technical Indicators
Market Signals| Indicator | BDRX | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 47.14 |
| Support Level | $4.00 | $0.58 |
| Resistance Level | $8.94 | $0.82 |
| Average True Range (ATR) | 1.09 | 0.07 |
| MACD | 0.33 | -0.01 |
| Stochastic Oscillator | 72.28 | 33.00 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.